Aetion
Arvind co-leads EDBI’s investment activities in the U.S. across various sectors—enterprise SaaS, financial markets tech, health tech, and agrifood.
EDBI is the corporate venture arm of the Singapore Economic Development Board (EDB) and manages a multi-billion dollar fund investing across technology, health care, and emerging technology sectors.
He currently serves and/or served on the Boards of Druva, Livongo (LVGO/TDOC), Aetion, Hedvig (CVLT), Pico, Metricstream, and Taulia. He sourced and executed investments in Aetion, Vesta, Pico, Inari, and Memphis Meats. Arvind also worked on Walkme, Velocloud (VMW), Sprinklr, and Pear Therapeutics, and managed portfolios for Crisp Media (acquired by Quotient Technology) and Quantcast.
Prior to joining EDBI, he was based out of Mumbai, India, served with the EDB as Director (India | Sri Lanka) for 3 years, and orchestrated Indian enterprise investments into Singapore. Arvind brings depth in networks spanning multiple sectors across the Indian subcontinent, southeast Asia, and the U.S.
In addition, Arvind was with Singapore’s Public Service and involved in strategizing and executing industry development work for the Energy & Chemicals and Infrastructure sectors at the EDB in Singapore. His contribution included helping the EDB shape Clifford Capital, Singapore’s first and only government-backed infrastructure project finance company, which was brought about with the support of Ministry of Finance/government and private sector banks.
Arvind started work with Load Control Technologies, a NDT-centric start-up in Philadelphia, as an enterprise sales engineer with a focus on building and converting sales pipeline with F100 companies.
He graduated with a Bachelor's in Chemical Engineering (Honours) from the National University of Singapore and pursued technopreneurship studies at the University of Pennsylvania (SEAS | Wharton) on a scholarship.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Aetion
9 followers
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care’s modern era.